Pre-earnings options volume in Crispr Therapeutics is normal with calls leading puts 19:5. Implied volatility suggests the market is anticipating a move near 7.4%, or $3.65, after results are released. Median move over the past eight quarters is 4.4%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Vertex Pharmaceuticals (NASDAQ:VRTX) Slides despite Raising Revenue Guidance
- CRSP Earnings this Week: How Will it Perform?
- JMP Securities healthcare analysts hold an analyst/industry conference call
- CRISPR Therapeutics Nears 52-Week Low. Time to Buy?
- Crispr Therapeutics call volume above normal and directionally bullish